NEUROSENSE THERAPEUTICS LTD
NRSNNASDAQTrading Snapshot
- Day Range
- $4.73 – $4.87
- 52-Week Range
- $4.86 – $26.64
- Volume
- $2.69B
- Avg Volume
- $2.57B
- Shares Outstanding
- 1.8M
- Next Earnings
- Dec 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $293,646
- P/E Ratio
- -0.6
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-8.71
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +18.0%
Why Investors Own NRSN
- ✓High-growth profile — revenue up -2.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 80% gross margin and 27% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
NEUROSENSE THERAPEUTICS LTD
NRSN
StockOtter · stockotter.spaceAbout NEUROSENSE THERAPEUTICS LTD
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
Management will participate in the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026 and will be available for one-on-one investor meetings during the conference CAMBRIDGE, Mass., Sept. 28, 2026
NeuroSense Provides Business Update and Progress for the First Half of 2026
CAMBRIDGE, Mass., Sept. 25, 2026 /PRNewswire/ -- Therapeutics Ltd.
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
Company presentation on Tuesday, September 15 at 4:30 p.m. ET Management will be available for one-on-one investor meetings during the conference CAMBRIDGE, Mass.
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
Three-part program - AI-enabled characterization of PrimeC's formulation advantage, an active-comparator trial against edaravone, and a streamlined pivotal pathway - is designed to strengthen PrimeC's differentiation, sh
NeuroSense Issues CEO Letter to Shareholders
CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada PR Newswire